Enliven Therapeutics (ELVN) COO trust sells 48,057 company shares

Q: Who is the reporting person in Enliven Therapeutics (ELVN)'s latest Form 4?

The reporting person is Anish Patel , who serves as the Chief Operating Officer of Enliven Therapeutics, Inc., and the shares involved are held through The Patel / Dong Family Trust.

Q: How many Enliven Therapeutics (ELVN) shares were sold in this Form 4?

The filing reports two sales of Enliven common stock: 48,057 shares at a weighted average price of $27.9842 and 243 shares at $28.50 , all held through The Patel / Dong Family Trust.

Q: Who actually holds the Enliven Therapeutics (ELVN) shares reported in this Form 4?

According to the footnotes, the shares are held by The Patel / Dong Family Trust Dated August 24, 2017 , for which Anish Patel serves as trustee.

Q: What is the purpose of the Rule 10b5-1 trading plan mentioned in the Enliven (ELVN) Form 4?

The sales were effected under a Rule 10b5-1 trading plan , which is described as a contract, instruction, or written plan for the purchase or sale of the issuer’s equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Q: When was the Rule 10b5-1 plan for the Enliven Therapeutics (ELVN) insider adopted?

The Form 4 states that the Rule 10b5-1 trading plan was adopted on September 30, 2024 by Anish Patel and The Patel / Dong Family Trust.

Q: Were the Enliven Therapeutics (ELVN) sales executed in a single trade or multiple trades?

One of the transactions was executed in multiple trades at prices ranging from $27.50 to $28.38 , with the reported price reflecting the weighted average sale price .

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Enliven Therapeutics, Inc. reported an insider transaction involving its Chief Operating Officer, Anish Patel, through an associated family trust. On January 9, 2026, The Patel / Dong Family Trust, for which Patel serves as trustee, sold 48,057 shares of Enliven common stock at a weighted average price of $27.9842, and an additional 243 shares at $28.50.

The filing states these sales were made under a Rule 10b5-1 trading plan adopted on September 30, 2024, which is a pre-arranged plan for trading the issuer’s equity securities. After these transactions, the trust held 215,011 shares of Enliven common stock, all reported as indirectly owned.

Insider Trade Summary

Net Seller: 48,300 shares ($1,351,762)

Net Sell 2 txns

Insider Patel Anish

Role CHIEF OPERATING OFFICER

Sold 48,300 shs ($1.35M)

Type	Security	Shares	Price	Value
Sale	Common Stock	48,057	$27.9842	$1.34M
Sale	Common Stock	243	$28.50	$7K

Holdings After Transaction: Common Stock — 215,254 shares (Indirect, See footnote)

Footnotes (1)

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust"). This transaction was executed in multiple trades at prices ranging from $27.50 to $28.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held by The Patel / Dong Family Trust.

Form 4 Insider Transactions: What Each Field Means →

01/13/2026 - 05:54 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Anish

(Last)

(First)

(Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER

80301

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/09/2026		S⁽¹⁾		48,057	D	$27.9842⁽²⁾	215,254	I	See footnote⁽³⁾
Common Stock	01/09/2026		S⁽¹⁾		243	D	$28.5	215,011	I	See footnote⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").

2. This transaction was executed in multiple trades at prices ranging from $27.50 to $28.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. The shares are held by The Patel / Dong Family Trust.

	/s/ Ben Hohl, by power of attorney	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the reporting person in Enliven Therapeutics (ELVN)'s latest Form 4?

The reporting person is Anish Patel, who serves as the Chief Operating Officer of Enliven Therapeutics, Inc., and the shares involved are held through The Patel / Dong Family Trust.

How many Enliven Therapeutics (ELVN) shares were sold in this Form 4?

The filing reports two sales of Enliven common stock: 48,057 shares at a weighted average price of $27.9842 and 243 shares at $28.50, all held through The Patel / Dong Family Trust.

Who actually holds the Enliven Therapeutics (ELVN) shares reported in this Form 4?

According to the footnotes, the shares are held by The Patel / Dong Family Trust Dated August 24, 2017, for which Anish Patel serves as trustee.

What is the purpose of the Rule 10b5-1 trading plan mentioned in the Enliven (ELVN) Form 4?

The sales were effected under a Rule 10b5-1 trading plan, which is described as a contract, instruction, or written plan for the purchase or sale of the issuer’s equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

When was the Rule 10b5-1 plan for the Enliven Therapeutics (ELVN) insider adopted?

The Form 4 states that the Rule 10b5-1 trading plan was adopted on September 30, 2024 by Anish Patel and The Patel / Dong Family Trust.

How many Enliven Therapeutics (ELVN) shares does the trust hold after the reported sales?

After the reported transactions, The Patel / Dong Family Trust is shown as holding 215,011 shares of Enliven common stock, reported as indirectly owned.

Were the Enliven Therapeutics (ELVN) sales executed in a single trade or multiple trades?

One of the transactions was executed in multiple trades at prices ranging from $27.50 to $28.38, with the reported price reflecting the weighted average sale price.